		Transcriptional Regulation Co-Immunoprecipitation DNA Repair Luciferase Reporter Assay Nuclear Receptor ELISAs Supershift & Gelshift Assays Transcription Factor ELISA Epigenetics & Chromatin Chromatin Assembly Chromatin IP DNA Damage – Phospho-H2AX DNA Methylation Histone Acetyltransferase Activity (HAT) Histone Deacetylase Activity (HDAC) Histone Modification ELISAs Histone Purification Methylated Histones Protein Modification GTPase Activation Assay Kinase Assay Substrate Mitosis Assays Nitric Oxide Quantitation Phospho-Protein Detection Sandwich ELISAs SUMOylation Antibodies, Extracts & Proteins Antibodies Cell Extracts Recombinant Proteins Fluorescence & Labeling Albumin Quantification Cell Viability Assay Fluorescent Dyes & Labeling Immunofluorescence Live Cell Membrane Staining Mitosis Determination Protein and Extract Quantification Protein Labeling & Translocation Sample Preparation Fluorescent Dye Labeling Mitochondrial Separation mRNA Isolation Normalization Nuclear & Cytoplasmic Extraction Protein & Extract Quantification Transfection & Expression Competent E. coli Gene Silencing Protein Transfection Staining Reagents Bioinformatics & Text Mining TimeLogic® Biocomputing Solutions AKS 2

Press Room

Siena Biotech SpA Extends License of AKS2 Literature Mining System

2007-01-27

Bioalma (Madrid, Spain), a bioinformatics development company, and its distribution partner, Active Motif (Carlsbad, CA) are pleased to announce that Siena Biotech S.p.A. (http://www. sienabiotech.com) has extended its license of AKS² (almaKnowledgeServer™). AKS² has provided Siena Biotech a rapid way to explore not only disease, gene, and compound topics found in published literature but also drug, symptom, and biomedical relationships as well. Siena Biotech will use the knowledge mining system to explore results obtained with their comprehensive proteomics platform.

"The newly designed AKS² will support our disease-based research." Dr. Georg C. Terstappen, Vice President Discovery Research at Siena Biotech S.p.A., explained. "We have been working with Bioalma for some time now and the new AKS² will help us extract knowledge from the data generated in our high-throughput experiments."

Juan Carlos del Castillo, CEO of Bioalma, commented, "Our current AKS² customers continue to see the value of text mining and how it helps their drug discovery efforts. I am happy Siena Biotech has selected AKS² as one of their scientific knowledge providers."

BROWSE BY: